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Abstract 
Sickle Cell Disorder (SCD) is a congenital
hemoglobinopathy. There is little in literature
regarding the psychological variables affecting
individuals living with SCD and all of the sig-
nificant people around them. There are also
limited numbers of trained clinical psycholo-
gists and genetic counselors to cater for the
psychotherapeutic needs of individuals living
with SCD. Even among those who have been
trained, only a few might have fully grasped
the complexities of the disease pathology. 
Early  understanding  of  its  pathological
nature,  sources,  types,  complications,  patho-
physiological  basis,  and  clinical  severity  of
symptoms among clinical psychologists, genet-
ic counselors and psychotherapists, as well as
general  medical  practitioners,  could  guide
them in providing holistic care for dealing with
and  reducing  pain  among  individuals  living
with SCD. It could allow risk-based counseling
for families and individuals. It could also justi-
fy the early use of disease-modifying or cura-
tive interventions, such as hydroxyurea (HU),
chronic transfusions (CTs), or stem-cell trans-
plantation  (SCT)  by  general  medical  practi-
tioners. Hence, the need for this paper on the
pathophysiology of SCD.
Introduction
Sickle cell disorder (SCD), also known as
drepanocytosis, is a quadrumvirate of anemia
and its sequelae, pain syndromes, organ dam-
age including infection, and comorbid condi-
tions.1-6 It is a chronic blood disorder charac-
terized  by  red  blood  cells  that  assume  an
abnormal,  rigid,  sickle  shape.  The  striking
deformity of the red blood cells led to the disor-
der  being  termed  ‘sickle  cell  anemia’7 and
‘sickle cell disease’,8 names that reflected the
subsequent acceptance that erythrocyte distor-
tion  was  central  to  the  development  of  its
symptoms.  In  1917,  Emmel  noted  that  the
degree of erythrocyte deformation varied with
time9 and Hahn and Gillespie7 demonstrated
that this eponymous change was induced by
deoxygenation. 
This disorder usually presents early in child-
hood  and  affects  millions  throughout  the
world. It occurs more commonly in people (or
their descendants) from parts of tropical and
sub-tropical regions where malaria is or was
common.  One-third  of  all  aboriginal  inhabi-
tants of Sub-Saharan Africa, Spanish-speaking
regions  (South  America,  Cuba,  Central
America),  Saudi  Arabia,  India,  and  Mediter-
ranean countries such as Turkey, Greece, and
Italy, carry the gene.* This is because in areas
where malaria is common, there is a survival
value in carrying only a single sickle-cell gene
(sickle cell trait).° Those with only one of the
two alleles of the sickle cell disorder are more
resistant to malaria, since the infestation of
the malaria plasmodium is halted by the sick-
ling of the cells which it infests. In the US, it
affects around 72,000 people, most of whose
ancestors  come  from  Africa.6 The  disorder
occurs  in  about  1  in  500  African-American
births and 1 in 1,000-1,400 Hispanic-American
births. About 2 million Americans, or 1 in 12
African Americans, carry the sickle cell trait.
SCD is considered the most common mono-
genic disease in Brazil. 
As a generation of individuals with sickle
cell  disorders  and  thalassemia  ages,  new
chronic  complications  of  these  hemoglo-
binopathies  develop,  several  of  which  are
potentially lethal and clinically multi-systemic
with a great variability of manifestations mod-
ulated by genetic and environmental factors.
Early understanding of its pathological nature,
sources, types, complications, pathophysiologi-
cal  basis,  and  clinical  severity  of  symptoms
among  clinical  psychologists,  genetic  coun-
selors and psychotherapists, as well as general
medical practitioners, could guide them in pro-
viding holistic care for dealing with and reduc-
ing pain among individuals living with SCD.
However, there is little in literature concerning
the psychotherapeutic management of symp-
toms and crises of SCD. There are also limited
numbers of trained clinical psychologists and
genetic counselors to cater for the psychother-
apeutic  needs  of  individuals  living  with  the
disease.  Even  among  those  who  have  been
trained, only a few of them might have fully
grasped the complexities of the pathology of
SCD. Hence, the need for this paper.
Types of sickle cell disorder
Sickle  cell  disorder  denotes  all  genotypes
that contain at least one sickle gene in which
°Sicklecell.md 
*Sicklecell.md  FAQ:  "Why  is  Sickle  Cell
Anaemia only found in Black people?
hemoglobin S (HbS) makes up at least half of
the  hemoglobin  present.  Globally,  sickle  cell
disorders  include  sickle  cell  genotypes  (Hb
SS),  and  at  least  five  other  major  hemoglo-
binopathies in which Hb S is associated with
abnormal  hemoglobin.  For  example,  sickle
beta-thalassemia  syndromes  (HbS-ʲ-0  tha-
lassemia with variable levels of Hb A), HbS– ʲ
Thal  HbSC  disorder,  HbS/hereditary  persist-
ence of fetal hemoglobin (S/HPHP), HbSE syn-
drome, rare combinations of HbS with HbD Los
Angeles,  HbO  Arab,  G-Philadelphia,  among
others. SS and Sʲ0 thalassemia have similar
clinical  presentation.  SC  and  S  Sʲ0+ tha-
lassemia  have  milder  presentation  than  SS,
but have an increased risk of proliferative sick-
le retinopathy. Risk of central nervous system
(CNS)  complications  for  patients  with  Sʲ0-
thalassemia and the rare SOArab, is similar to
that for SS patients. For this reason, individu-
als with SS, Sʲ0, and SOArab genotypes are
often grouped in clinical studies and in the
term sickle cell anemia (SCA). Cerebral injury
is one of the severe complications of SCA.
Pathophysiological mechanisms
precipitating sickle cell disorder crisis
Current treatment and understanding of SCD
require an appreciation of the complexity of its
basic pathophysiology. These are the complex
mechanisms  by  which  abnormal  hemoglobin
produces  the  profound,  systemic,  and  severe
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effects of SCD.10,11 These include the sickling
process, hemoglobin cyclic polymerization, the
generation of dense, dehydrated red cells, coag-
ulation  abnormalities  and  the  interaction
between sickle red cells and abnormal activated
vascular endothelial cells, among others.
Sickling process
This is the pathophysiological basis of SCD.
It is markedly accelerated when intracellular
concentration of Hb S is increased. Sickle cells
are short lived and can interact with endothe-
lial cells, leukocytes, platelets, and other plas-
ma components. The sickling occurs because
of  a  mutation  in  the  hemoglobin  gene.  It
begins with the substitution of valine for glu-
tamic acid at the sixth position of the beta-glo-
bin chain. The association of heme plus 2 nor-
mal a-globin and 2 abnormal ʲ-globin chains
forms  Hb  S.  It  normally  carries  oxygen  but
begins to form semi-solid aggregate structures
once oxygen is unloaded to the tissues. These
Hb S aggregates distort RBCs and decrease the
cells'  flexibility.  Repeated  deoxygenation
cycles  cause  permanent  red-cell  damage
(Figure 1).
In 1940, Ham and Castle noted that sickling
leads to a risk of various inflammatory compli-
cations characterized by vascular endothelium
activation and increased blood cell-endotheli-
um  interactions.12 They  suggested  that  any
condition that caused a “primary increase in
the plasma viscosity” would delay passage of
the erythrocytes through the capillaries, pro-
ducing an increase in sickling and a “vicious
cycle” of venous stasis, further sickling, capil-
lary congestion, and infarction. 
Hemoglobin cyclic polymerization or ery-
throcyte density (see Table 1) 
The polymerization of deoxy Hb S is essen-
tial  to  vaso-occlusive  phenomena.10 Mature
erythrocytes are derived from committed ery-
throid progenitor cells through series of mitot-
ic divisions and maturation phases. Erythro-
poietin, a humoral agent produced mainly by
the kidneys, stimulates erythropoiesis by act-
ing on committed stem cells to induce prolifer-
ation and differentiation of erythrocytes in the
bone marrow. Tissue hypoxia (lack of oxygen)
is the main stimulus for erythropoietin produc-
tion. Nucleated red cell precursors in the bone
marrow are collectively called normoblasts or
erythroblasts. RBCs that have matured to the
non-nucleated stage gain entry to the periph-
eral blood. Once the cells have lost their nuclei,
they  are  called  erythrocytes.  Young  erythro-
cytes  that  contain  residual  RNA  are  called
reticulocytes. 
In  SCD,  young,  “sticky”  erythrocytes  con-
taining  Hb  S  adhere  to  the  post-capillary
venule, narrowing its lumen. This decreases
velocity of blood flow and increases erythrocyte
transit  time.  Subsequently,  Hb  S  becomes
deoxygenated as the stagnant blood unloads
more oxygen to surrounding tissues. Deoxy-
hemoglobin S is much less soluble than the
oxygenated variety, and a hydrophobic interac-
tion between Hb S ʲ chains precipitates a dou-
ble  stranded,  rope-like  polymer  that  causes
erythrocyte sickling and rigidity. ISCs become
wedged and occlude the small vessels, produc-
ing ischemia and eventually necrosis in the
affected  vascular  territory,  initiating  an
inflammatory  response  and  neuropeptide
release (Figure 2). These last  two factors pro-
duce pain, which is a potent stimulator of the
sympathetic  nervous  system.  Classic  norepi-
nephrine-mediated  tachycardia,  tachypnea,
and related hypertension may be noted. The
high sympathetic activity also produces vaso-
constriction,  further  decreasing  distal  blood
flow and renewing the sickling cycle. 
In  1997,  Bunn  noted  that  erythrocytes  in
patients  with  SCD  are  more  adherent  to  the
endothelium than in normal subjects, and the
degree of adherence is associated with disease
severity.10 The erythrocyte a4ʲ1 integrin com-
plex  interacts  with  endothelial  VCAM-1  and
fibronectin. Additionally, erythrocyte CD36 and
sulphated  glycans  interact  with  endothelial
CD36.  Endothelial  factors  VCAM-1  and  fibro-
nectin are up-regulated by infectious or inflam-
matory processes via tumor necrosis factor-a;
the  CD36  interactions  are  mediated  by  von
Willebrand factor and thrombospondin from acti-
vated platelets. These interactions explain infec-
tion as a cause of increased frequency of VPC. 
The rate and extent of ʲS polymer formation
depends primarily on the degree of erythrocyte
oxygenation,  the  concentration  of  intra-ery-
throcyte hemoglobin, and the concentration of
hemoglobin  F.10 Physical  chemistry  dictates
that higher concentrations of solutes promote
precipitation;  therefore,  as  the  erythrocyte
becomes  dehydrated,  the  high  intra-erythro-
cyte  hemoglobin  concentration  encourages
ʲS-ʲS polymerization. The potassium-chloride
and calcium-potassium erythrocyte ion chan-
nels are particularly important.10 Hb S and C
mutations both lead to increased potassium-
chloride co-transport, resulting in the forma-
tion  of  target  cells,  erythrocyte  dehydration,
increased  intra-erythrocyte  hemoglobin,  and
promotion  of  ʲS  polymerization.  The  Ca++-
activated K+ efflux (Gardos) channel also pro-
duces dehydration/polymerization, particularly
when activated by the acidotic environment in
stagnant capillary beds (Figure 3). 
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Figure 1. Molecular and cellular changes of
hemoglobin  S.12 Legend:  ʲ6Glu⇒Val.
Deoxy Hb S polymer forms with low O2,
Causes  irreversibly  sickled  cells.  Under  a
variety  of  circumstances,  different  organs
are susceptible: esp. bone, spleen, and lung.
Figure 2. Oxy versus deoxyhemoglobin.15
Legend: a = Alpha globins; ʲ= Beta glo-
bins.
Figure  3.  Red  cell  morphology.16 Legend:
RBC: red blood cells i) Endothelial activa-
tion;  ii)  WBC  adhesion;  iii)  RBC-WBC
interactions;  iv)  vasoocclusion.  Lumen
obstruction  results  from  interaction  b/w
WBC, RBC, platelets, plasma proteins &
vascular endothelium.
Table 1. Polymerization of deoxy-Hb.14
Sickling-unsickling Sickling-unsickling
anemia RSC
ISC
Microvascular occlusion
Tissue ischemia
Tissue damage
Pain perception
Legend: Polymer formation as a function of hemoglobin concentra-
tion for mixtures of Hb S/Hb A2 variants. 
Polymerization of deoxygenated Hb S is the primary event in the
molecular pathogenesis of sickle cell disease, resulting in a distor-
tion of the shape of the erythrocyte and a marked decrease in its
deformability. These rigid cells are responsible for the vasoocclu-
sive phenomena that are the hallmark of the disease.[page 12] [Hematology Reports 2010; 2:e2]
Erythrocyte maturation, survival and function 
Reticulocytes  are  released  from  the  bone
marrow into the peripheral blood where they
mature  into  erythrocytes,  usually  within  24
hours. Mature RBCs have a lifespan of 100-120
days and senescent RBCs are removed by the
spleen. Three areas of RBC structure/metabo-
lism crucial for normal erythrocyte maturation,
survival and function are: i) the RBC mem-
brane; ii) hemoglobin structure and function;
and iii) cellular energy. Defects or problems
associated  with  any  of  these  will  result  in
impaired RBC survival. The RBC must be flex-
ible in order to squeeze through the capillaries
of the spleen. Flexibility is a property of the
membrane and the fluidity of the cell’s content.
Any decrease in flexibility results in a decrease
in RBC deformability and a decrease in RBC
survival in passage through the spleen. 
The  RBC  membrane  is  a  semi-permeable
lipid bilayer supported by a protein cytoskele-
ton (contains both integral, e.g. glycophorins,
and peripheral proteins). The constituents of
the RBC membrane are phospholipids and cho-
lesterol.  Exchange  between  phospholipids  in
the  membrane  and  the  plasma  may  occur.
Since the fatty acid content of the diet and the
plasma are correlated, changes in the diet may
have an effect on the fatty acid composition of
the  phospholipids  in  the  RBC  membrane
which can adversely affect the flexibility of the
RBC  and  may  result  in  an  RBC  with  a
decreased  survival  time.  Membrane  choles-
terol  exists  in  free  equilibrium  with  plasma
cholesterol.  Therefore,  an  increase  in  free
plasma cholesterol results in an accumulation
of  cholesterol  in  the  RBC  membrane.  RBCs
with  increased  cholesterol  appear  distorted
and  the  increased  cholesterol  results  in  the
formation of target cells and acanthocytes. An
increase  in  the  cholesterol  to  phospholipid
ratio results in a cell membrane that is less
deformable  and,  therefore,  the  RBC  has  a
decreased survival time.
Glycophorin  is  a  single-pass  trans-mem-
brane  integral  protein.  Glycophorin,  which
functions as cationic pumps that require ATP,
helps the RBC maintains its volume and water
homeostasis  by  controlling  the  intracellular
concentrations  of  Na+ and  K+.  ATP  is  also
required in the Ca++ pump system that pre-
vents excessive intracellular build-up of Ca++.
In ATP depleted cells, there is an intracellular
build-up of Na+ and Ca++ and a loss of K+ and
water. This leads to dehydrated, rigid cells that
are culled by the spleen. Any abnormality that
increases  membrane  permeability  or  alters
cationic  transport  may  lead  to  reduced  RBC
survival.
Maintenance of Hb function requires active
RBC metabolic pathways for ATP production.
The  major  peripheral  protein  is  spectrin,
which is a heterodimer consisting of two anti-
parallel chains helically intertwined. It under-
lies the membrane, which maintains the struc-
tural integrity of the cell. It interacts with other
peripheral proteins such as actin and tropo-
myosin to form a skeleton of microfilaments on
the inner surface of the membrane. It binds
with various proteins on the inner surface of
the  cell  membrane.  For  example  band  3,  a
trans-membrane  protein,  is  attached  to
ankyrin,  which  binds  spectrin,  a  covalently-
bound  membrane  protein  called  band  4.1
which  binds  spectrin  in  a  complex  with
adducin, actin and tropomyosin. This strength-
ens the membrane and gives it its elastic prop-
erties. For spectrin to participate in this inter-
action, it must be phosphorylated by a protein
kinase that requires ATP. Thus, a decrease in
ATP leads to reduced phosphorylation of spec-
trin. Unphosphorylated spectrin can no longer
bind to actin to give the membrane its elastic
properties. This then leads to a loss in mem-
brane deformability and reduced  RBC survival
time (Figure 4). 
Abnormalities of hemoglobin structure and
function
Hemoglobin is a two-way respiratory carrier,
transporting oxygen from the lungs to the tis-
sues  and  facilitating  the  return  transport  of
carbon  dioxide.  In  the  arterial  circulation,
hemoglobin has a high affinity for oxygen and
a low affinity for carbon dioxide, organic phos-
phates, and hydrogen and chloride ions. In the
venous circulation, these relative affinities are
reversed (Figure 5). 
Hb occupies 33% of the RBC volume and 90-
95% of the dry weight. Sixty-five percent of the
hemoglobin synthesis occurs in the nucleated
stages of RBC maturation and 35% during the
reticulocyte  stage.  Normal  Hb  consists  of  4
heme groups, which contain a protoporphyrin
ring plus iron, and globin, which is a tetramer
of 2 pairs of polypeptide chains. Normal Hb
production is dependent upon three processes:
adequate  iron  delivery  and  supply,  adequate
synthesis of protoporphyrins and adequate glo-
bin synthesis. Iron is delivered to the RBC pre-
cursor by transferrin. It goes to the mitochon-
dria where it is inserted into protoporphyrin to
form  heme.  Synthesis  of  protoporphyrin
begins in the mitochondria where glycine plus
succinyl CoA results in delta aminolevulenic
acid (ʴ ALA).  
Abnormalities  of  hemoglobins  were  first
described in the peripheral blood of an anemic
patient from the West Indies by the Chicago
physician  Robert  Herrick.13 In  1957,  Ingram
demonstrated  that  sickle  cell  anemia  was
caused by the replacement of one of the 287
Article
Figure  4.  RBC  membrane  structure.17 Legend:  I  =  Integral  Proteins; P  =  Peripheral
Proteins; hemoglobin occupies 33% of the RBC volume and 90-95% of the dry weight;
65% of the hemoglobin synthesis occurs in the nucleated stages of RBC maturation and
35% during the reticulocyte stage; normal hemoglobin consists of 4 heme groups, which
contain a protoporphyrin ring plus iron, and globin, which is a tetramer of 2 pairs of
polypeptide chains.
Figure 5. a= Alpha Chains. The a-globin
genes  are  on  chromosome  16.  ʲ=Beta
Chains. The ʲ-globin genes are on chromo-
some 11. Fe2+ = Ferrous indicates a bivalent
iron  compound  (+2  oxidation  state),  as
opposed to ferric, which indicates a triva-
lent iron compound (+3 oxidation state).
Heme = is a prosthetic group that consists
of an iron atom contained in the center of a
large heterocyclic organic ring called a por-
phyrin.  Not  all  porphyrins  contain  iron,
but  a  substantial  fraction  of  porphyrin-
containing  metalloproteins  have  heme  as
their prosthetic group; these are known as
hemoproteins.[Hematology Reports 2010; 2:e2]
amino acid residues in the half molecule of
Hb.14 This finding improved understanding of
the disorder at the molecular level, since for
the first time a point mutation in a structural
gene was shown to cause the substitution of
one amino acid in the protein controlled by
that gene. Furthermore, in 1954, Allison indi-
cated that the accumulation of the sickle cell
gene  in  malarial  regions  of  the  world  is  an
illustration of Darwin’s theory of evolution by
natural selection.15 To date, well over 200 vari-
ants  and  abnormal  hemoglobins  have  been
described.
Hemoglobin S (Hb S) results from a single
base-pair mutation in the gene for the beta-
globin chain of adult hemoglobin. An adenine-
thymine  substitution  in  the  sixth  codon
replaces glutamic acid with valine in the sixth
amino  acid  position  of  the  beta-globin
chain.10,16 This  substitution  yields  electro-
phoretically distinct Hb.17 In the deoxygenated
form of Hb S, the beta-6 valine becomes buried
in a hydrophobic pocket on an adjacent beta-
globin chain, joining the molecules together to
form  insoluble  polymers.10 In  sufficient  con-
centration, these insoluble polymers give rise
to the classical sickle morphology. This process
causes  severe  damage  to  the  red  cell  mem-
brane.  Sickled  red  cells  may  then  aggregate
and go on to cause microvascular obstruction.
Also,  these  abnormal  red  cells  adhere  to
endothelial cells18 and can interact with vari-
ous cytokines.19
Endothelial dysfunction 
The  vessel  wall  endothelium  undoubtedly
plays  a  role  in  the  vascular  pathobiology  of
Sickle Cell Disorder. In individuals with SCD, a
state  of  endothelial  dysfunction  is  observed.
Endothelial cells (ECs) line the inner surface
of blood and lymphatic vessels, and play impor-
tant roles in the development and remodeling
of vasculature, maintenance of vascular tone,
blood fluidity, coagulation, nutrient exchange,
and organ development. Endothelial dysfunc-
tion is characterized by a shift of the actions of
the endothelium toward reduced vasodilation,
a  proinflammatory  state,  and  prothrombic
properties. It is associated with most forms of
cardiovascular disease, such as hypertension,
coronary artery disease, chronic heart failure,
peripheral artery disease, diabetes, and chron-
ic renal failure. Mechanisms that participate
in  the  reduced  vasodilatory  responses  in
endothelial dysfunction include reduced nitric
oxide  generation,  oxidative  excess,  and
reduced production of hyperpolarizing factor.
Upregulation of adhesion molecules, genera-
tion  of  chemokines  such  as  macrophage
chemoattractant peptide-1, and production of
plasminogen  activator  inhibitor-1  participate
in the inflammatory response and contribute
to  a  prothrombic  state.  Vasoactive  peptides
such as angiotensin II and endothelin-1, the
accumulation of asymmetric dimethylarginine,
an endogenous nitric oxide inhibitor, hyperc-
holesterolemia,  hyperhomocysteinemia,
altered  insulin  signaling,  and  hyperglycemia
can contribute to these different mechanisms.
Detachment and apoptosis of endothelial cells
(anoikis) are associated phenomena. 
Depletion of nitric oxide in sickle cell anemia
Nitric oxide (NO) is an uncharged free rad-
ical that is produced during the enzymatic con-
version of L-arginine to L-citrulline by mem-
bers of the NOS family of proteins in endothe-
lial cells.20 Three members of the family have
been  identified:  endothelial  NOS  (eNOS  or
NOS3), neuronal NOS (nNOS or NOS1) and
inducible  NOS  (iNOS  or  NOS2),  with  eNOS
and  nNOS  both  functioning  in  a  calcium-
dependent and independent fashion, and iNOS
functioning  in  a  calcium  independent  fash-
ion.20 The bioavailability of nitric oxide (NO)
within the vascular wall is limited by superox-
ide  anions  (O2–)  in  sickle  cell  disease.  The
amount of free, bioactive NO in the vascular
wall  is  determined  by  the  activity  of  the
endothelial NO synthase (eNOS) and by NO-
scavenging mechanisms, such as the reaction
of  NO  with  superoxide  anions  (O2–).21
Numerous  studies  have  demonstrated  that
indeed the local O2– concentration is the main
limiting factor for the availability of bioactive
NO in healthy and diseased vessels.21
Nitric oxide (NO) was identified originally
as the endothelium derived relaxation factor
that mediates vasodilation in a soluble guany-
late cyclase (sGC) in a dependent manner in
smooth  muscle22 to  counter  the  processes
induced by hypoxia. Because NO readily diffus-
es through cell membranes and can bind with
high affinity to heme-containing proteins (e.g.
sGC)  or  nitrosylate  proteins,  it  has  been
reported to exhibit complex pleiotropic effects
and is central to many aspects of physiology
and pathology. 
Nitric oxide is a regulator of smooth muscle
tone and platelet activation, and reductions in
nitric oxide plasma levels lead to smooth mus-
cle  dystonias,  including  hypertension,  gas-
trointestinal  contractions,  and  erectile  dys-
function, as well as clot formation (Figure 6). 
Nitric oxide is a critical regulator of vasodi-
lation  and  vascular  homeostasis.  Since  the
reaction of nitric oxide with the vast amounts
of  intravascular  oxyhemoglobin  (16  g/dL)  is
fast (107M-1s-1) and irreversible, it would be
expected  that  nitric  oxide  produced  by
endothelium would be immediately scavenged
by hemoglobin and would, therefore, be inca-
pable of paracrine diffusion from endothelium
to  vascular  smooth  muscle.23,24 However,  the
ability of hemoglobin to react with nitric oxide
produced by endothelium is limited by com-
partmentalization  of  Hb  inside  the  erythro-
cyte.25-27 Thus, the evolution of the erythrocyte
Article
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Figure 6. Depletion of nitric oxide in sickle
cell anemia.29 Legend: Sickle cell disease
Hemolysis  Arginine  ￘ NO  ￘.  During
intravascular  hemolysis,  hemoglobin  is
released into the plasma where it is normal-
ly  cleared  by  the  hemoglobin  scavengers
haptoglobin,  CD163,  and  hemopexin.
Haptoglobin-hemoglobin  complexes  bind
to CD163 on the surface of macrophages/
monocytes  initiating  endocytosis  and
degradation of the complex. Hemoglobin
also  releases  ferric  heme  on  oxidation,
which is bound by hemopexin and degrad-
ed  by  hepatocytes  in  the  liver.  Excessive
hemolysis  saturates  and  depletes  these
hemoglobin removal systems and leads to a
build-up of hemoglobin and heme in the
plasma.  Plasma  hemoglobin  and  heme
mediate direct proinflammatory, prolifera-
tive,  and  pro-oxidant  effects  on  vessel
endothelial cells. NO is normally generated
from L-arginine in vessel endothelial cells
by the enzyme nitric oxide synthase (NOS).
NO  maintains  smooth  muscle  relaxation
and inhibits platelet activation and aggre-
gation, thereby regulating vessel tone and
promoting  organ  system  homeostasis.
During intravascular hemolysis, NO avail-
ability can be severely limited by its reac-
tion with oxyhemoglobin (NO scavenging)
and by the breakdown of the substrate for
NO synthesis, L-arginine, by the red cell
enzyme arginase, despite elevated levels of
NOS (decreased NO synthesis). NO deple-
tion  results  in  decreased  activation  of
guanylate cyclase, an enzyme required for
the  generation  of  cyclic  guanine  mono-
phosphate (cGMP). Decreased cGMP lev-
els  disrupt  regulation  of  smooth  muscle
tone resulting in dystonias, including sys-
temic and pulmonary hypertension, erec-
tile dysfunction, dysphagia, and abdominal
pain. Decreased cGMP levels through the
depletion of NO can also lead to platelet
activation and aggregation, promoting clot
formation.  GTP  indicates  guanosine  5’-
triphosphate.  (Modified  from  JAMA
2009).[page 14] [Hematology Reports 2010; 2:e2]
may be considered a mechanism of reducing
toxicity while ensuring separation of the criti-
cal respiratory transport machinery needed for
efficient oxygen delivery from the endotheli-
um. Moreover, multiple systems have evolved
to control the level of cell-free Hb in the plasma
during  normal  physiological  hemolysis,  pre-
sumably  to  curtail  the  deleterious  effects  of
plasma Hb on nitric oxide bioavailability and
endothelial function.
Inflammatory mediators
Interaction  of  inflammatory  mediators  or
nociceptive pain in SCD involves four major
pathophysiological processes that explain the
pain  experience  (Figure  7):  transduction,
transmission, modulation, and perception.28-33
Transduction  is  the  process  through  which
noxious inflammatory mediators (collectively
referred  to  as  inflammatory  soup,  including
prostaglandins,  histamines,  bradykinin,  H+,
K+, cytokines, serotonin, substance P, leuko-
trienes, and others) are generated by tissue
damage. These inflammatory mediators acti-
vate  nociceptors  by  converting  chemical  or
mechanical  energy  to  an  electrochemical
impulse in the primary afferent nerve fibers.
Interleukin-1 (IL-1) is an endogenous pyrogen
and also activates the cyclo-oxygenase gene,
which leads to synthesis of prostaglandins E2
and I2. Bradykinin, potassium, hydrogen ions,
and  serotonin  activate  nociceptive  afferent
nerve  fibers  and  evoke  a  pain  response.
Prostaglandins,  leukotrienes,  nerve  growth
factor,  and  bradykinin  sensitize  peripheral
nerve endings and facilitate the transmission
of painful stimuli that reach the cerebral cor-
tex  via  the  spinal  cord  and  the  thalamus.
Activated nociceptors release stored substance
P in peripheral nerves and in the spinal cord,
which  itself  facilitates  the  transmission  of
painful  stimuli.  Bradykinin  and  substance  P
also cause vasodilatation with extravasation of
fluids that can lead to local swelling and ten-
derness. Prostaglandins increase the effective
renal  blood  flow  and  effective  renal  plasma
flow  in  children  and  young  adults.34
Prostaglandins PGE2 and PGI2 infused directly
into the renal arteries of dogs increase renal
blood flow and provoke diuresis, natriuresis,
and kaliuresis.34 The painful stimulus is then
transmitted along A-ʴ and C peripheral nerve
fibers to the dorsal horn of the spinal cord,
where it may be enhanced or suppressed by
several receptors. Most important among these
is the N-methyl-D-aspartate (NMDA) receptor
at the dorsal horn that facilitates the transmis-
sion  of  the  painful  stimulus  once  activated.
From there, the stimulus crosses to the con-
tralateral  side  and  ascends  along  the
spinothalamic tracts to the thalamus, which is
a relay station, and interacts with the hypo-
thalamus, reticular formation (associated with
awareness and behavior), and the limbic sys-
tem, including the amygdala, the hippocampus
(associated  with  memory),  and  nucleus
accumbens. The limbic system also contains
the brain’s reward/pleasure circuit, as will be
discussed below. Modulation refers to descend-
ing fibers from the midbrain to the dorsal horn
that can inhibit the transmission of the painful
stimuli via endogenous endorphins, serotonin,
and norepinephrine. Taken together, commu-
nications  and  interactions  among  the  thala-
mus,  hypothalamus,  the  reticular  formation,
the limbic system, and the descending modula-
tion system enhance or ameliorate the intensi-
ty of pain perceived at the level of the cerebral
cortex (Figure 7). 
Although sickle cell pain is primarily a noci-
ceptive type of pain due to tissue damage, it
may  also  have  a  neuropathic  component35
characterized  by  sensations  of  burning,  tin-
gling,  shooting  numbness,  and  lancinating
pain    (i.e.  stabbing  pain,  from  lancinate,  to
stab,  from  the  Latin  lancināre,  lancināt-,  to
lacerate). These symptoms may occur in the
presence  or  absence  of  obvious  central  or
peripheral  nerve  injury.  The  mechanism  of
neuropathic  pain  presumably  involves  aber-
rant somato-sensory processing in the central
or  peripheral  nervous  system.  Mental  nerve
neuropathy, trigeminal neuralgia, acute proxi-
mal  median  mononeuropathy,  entrapment
neuropathy, and acute demyelinating polyneu-
ropathy have been described in SCD.3,36 A thor-
ough  history  and  physical  examination  help
determine whether sickle cell pain is associat-
ed with a neuropathic component that can be
managed  using  special  adjuvants,  including
anticonvulsants.
The pathology of sickle cell disorder
symptoms
Essentially,  the  multi-systemic  complica-
tions in SCD include a multitude of diagnostic
considerations classified as molecular patholo-
gy, biochemical pathology, cellular pathology,
vascular pathology and clinical pathology. 
Molecular pathology
In  molecular  terms,  sickle  cell  disease
(SCD) is caused by a single base mutation,
producing a single amino acid substitution at
position 6 of the ʲ chain of Hb, thus forming
HbS rather than the normal HbA. That is, SCD
is a group of chronic inherited disorders of Hb
in  which  the  affected  person  inherits  two
mutant globin genes from both parents; one of
these  genes  is  always  the  sickle  mutation.
That is a point mutation (GAGￆGTG) in the
ʲ-globin gene (HBB), a subunit of adult hemo-
globin A (HbA), results in the substitution of
valine for glutamic acid at the sixth amino acid
of  the  ʲ-globin  chain  (Glu6Val),  which  pro-
duces a Hb tetramer (a2/ʲ S2) that is poorly
soluble  when  deoxygenated.10 This  mutation
results  in  the  abnormal  sickle  hemoglobin
(HbS), when deoxygenated. This hemoglobin
(HbS) presents physical and chemical abnor-
malities  and  a  tendency  to  polymerization
under  certain  circumstances,  damaging  the
sickle erythrocyte. SCA is due to homozygosity
for the abnormal hemoglobin, hemoglobin S.
The  presence  of  HbS  associated  with  other
hereditary  variants  of  hemoglobin  such  as
hemoglobin  C,  D  and  S/  Sʲ0  thalassemia,
among  others,  characterizes  sickle  cell  dis-
ease.37-39
Biochemical pathology
The biochemical pathology of SCD involves
detoxication, GSH, oxidative stress and inflam-
mation. The first three are interrelated.
Detoxication  is  the  process  of  preventing
toxic entities from entering the body in the
first place. It refers to the reduction of the toxic
properties  of  a  substance  and  treatment
designed to assist in recovery from the toxic
effects of a drug. It begins with the participa-
tion of increased oxidative damage in SCD. Hb
S is more unstable than Hb A, contributing to
increased generation of free radicals,40 levels
of both total and reduced glutathione (GSH)
are  low,41 the  pentose  phosphate  pathway  is
impaired,42 and oxidative damage is present in
both proteins and lipids.41 Furthermore, in red
cells from human and other species, reduction
in GSH stimulates the KCl cotransporter (prob-
ably  KCC1).43,44 This  is  important  because
KCC1, in high K+ cells, mediates increased KCl
e ux and promotes cell dehydration. Low GSH
may account partially for the high activity of
KCC1 in Hb S cells.45Increased oxidative stress
in  Hb  S  cells,  causing  membrane  damage,
increased cell rigidity, altered cation perme-
ability and cell dehydration, will all contribute
to the chronic hemolysis and acute vaso-occlu-
sive events of SCD. The oxygenation status of
the red cell has other important consequences. 
The extent to which a cell is able to with-
stand  the  potentially  damaging  effects  of
oxidative stress is determined by the balance
between the rate at which oxidant species are
generated  and  the  capacity  of  metabolic
processes to produce antioxidants. Erythrocyte
glutathione  depletion  has  been  linked  to
hemolysis  and  oxidative  stress.  The  glu-
tathione (GSH) system is a major component
of  overall  antioxidant  defenses46 through
preservation of intracellular nicotinamide ade-
nine dinucleotide phosphate (NADPH) levels,
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Figure 7. Ballas figure on molecular mech-
anisms of pain.35[Hematology Reports 2010; 2:e2]
required for glutathione recycling. GSH is syn-
thesized de novo within all cells from gluta-
mate, cysteine and glycine in a series of reac-
tions  catalyzed  by  glutamate  cysteine  ligase
(also known as -glutamylcysteine synthetase,
EC 6.3.2.2) and -L-glutamyl-L-cysteine:glycine
ligase (also known as glutathione synthetase,
EC  6.3.2.3).  Glutamate  cysteine  ligase  cat-
alyzes the synthesis of the intermediate -L-glu-
tamyl-L-cysteine from glutamate and cysteine,
the rate-limiting step in GSH synthesis. 
The antioxidant defense systems include a
complex  of  interrelated  functions,  each  of
which tends to buffer the effects of the others.
There is abundant evidence that the GSH con-
centration in erythrocytes of individuals with
SCD is low and they also have increased oxida-
tive stress.47 It has been proposed that oxida-
tive damage of the membrane and ionic chan-
nels of the SCD erythrocyte alters its polymer-
ization and depolymerization kinetics result-
ing in the formation of irreversibly sickled cells
and  microvascular  occlusion.48-50 In  1998,
Gibson et al. noted that an increase in intracel-
lular concentrations of GSH inhibits the forma-
tion of dense cells and irreversibly sickled cells
in vitro by maintaining the sulfhydryl groups
of F-actin, a membrane structural protein in
the reduced form.49
Notwithstanding, there are two obvious gen-
eral  kinetic  mechanisms  for  the  decreased
intracellular GSH concentration, namely sup-
pressed synthesis and/or increased consump-
tion relative to synthetic capacity. In SCD there
is  indirect  evidence  for  protein  and  energy
deficiencies  relative  to  metabolic  demand.51
Additionally,  in  vivo kinetic  experiments  in
normal adults have shown that GSH turnover
is  suppressed  by  diets  deficient  in  sulfur
amino  acids52 and  by  diets  with  marginal
amounts of protein.53
Acute  inflammation  is  characterized  by
marked  vascular  changes,  including  vasodi-
latation, increased permeability, and the slow-
ing of blood flow, which are induced by the
actions  of  various  inflammatory  mediators.
Vasodilatation  occurs  first  at  the  arteriole
level,  progressing  to  the  capillary  level,  and
brings about a net increase in the amount of
blood present, causing the redness and heat of
inflammation.  Increased  permeability  of  the
vessels results in the movement of plasma into
the tissues, with resultant stasis due to the
increase in the concentration of the cells with-
in blood; a condition characterized by enlarged
vessels packed with cells. Stasis allows leuko-
cytes to marginate (move) along the endothe-
lium;  a  process  critical  to  their  recruitment
into the tissues. Normal flowing blood prevents
this as the shearing force along the periphery
of the vessels moves cells in the blood into the
middle of the vessel.
Cellular pathology
This refers to the platelets and coagulation
factors.  Platelets  (also  called  thrombocytes)
are tiny oval-shaped cells made in the bone
marrow.  They  help  in  the  clotting  process.
When a blood vessel breaks, platelets gather in
the area and help seal off the leak. Platelets
only  survive  about  nine  days  in  the  blood-
stream and are constantly being replaced by
new cells. Important proteins called coagula-
tion factors are critical to the clotting process.
Although platelets alone can plug small blood
vessel leaks and temporarily stop or slow bleed-
ing, the action of coagulation factors is needed
to produce a strong, stable clot. Platelets and
clotting  factors  work  together  to  form  solid
lumps  that  seal  leaks,  wounds,  cuts,  and
scratches, and to prevent internal bleeding and
bleeding  on  the  body  surfaces.  When  large
blood vessels are severed, the body may not be
able to repair itself through clotting alone. In
these cases, dressings or stitches are used to
help control bleeding. SCD is often referred to
as a hypercoagulable state54 because patients
manifest increased thrombin and fibrin gener-
ation,55-57 increased tissue factor procoagulant
activity,58 and  increased  platelet  activa-
tion56,57,59 even when they are in a non-crisis,
steady  state.  Furthermore,  thrombosis  may
contribute to the pathogenesis of several SCD-
related  complications.  For  example,  stroke,
caused by large vessel obstruction with super-
imposed  thrombosis,  often  occurs  in  SCD
patients.52Both pulmonary embolism and preg-
nancy-related  venous  thromboembolism
appear  to  occur  more  commonly  in  SCD
patients  than  in  appropriate  control
patients.60,61 The  coagulation  system  is  in  a
state of activation in "steady state" sickle dis-
orders  as  well  as  during  painful  crisis.  It
involves both a cellular (platelet) and a protein
(coagulation  factor)  component.  Coagulation
begins almost instantly after an injury to the
blood  vessel  has  damaged  the  endothelium
(lining of the vessel). This releases phospho-
lipid components called tissue factor and fib-
rinogen that initiate a chain reaction. Platelets
immediately form a plug at the site of injury;
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Figure 8. The Coagulation Cascade.72 Legend: this is the physiological coagulation cas-
cade used to describe a very complex step-by-step process that occurs in the body (in vivo)
when a blood vessel is injured. In the cascade, solid arrows indicate activation of a coagu-
lation factor by the factor above it in the cascade, dotted arrows indicate activation of fac-
tors V, VIII, XI and XIII by thrombin. The intrinsic cascade (which has less in vivo signif-
icance in normal physiological circumstances than the extrinsic cascade) is initiated when
contact is made between blood and exposed negatively charged surfaces. The extrinsic
pathway is initiated upon vascular injury which leads to exposure of tissue factor, TF (also
identified as factor III), a subendothelial cell-surface glycoprotein that binds phospho-
lipid. The green dotted arrow represents a point of cross-over between the extrinsic and
intrinsic pathways. The two pathways converge at the activation of factor X to Xa. Factor
Xa has a role in the further activation of factor VII to VIIa as depicted by the green arrow.
Active factor Xa hydrolyzes and activates prothrombin to thrombin. Thrombin can then
activate factors XI, VIII and V furthering the cascade. Ultimately the role of thrombin is
to convert fribrinogen to fibrin and to activate factor XIII to XIIIa. Factor XIIIa (also
termed transglutaminase) cross-links fibrin polymers solidifying the clot. HMWK = high
molecular weight kininogen. PK = prekallikrein. PL = phospholipid.[page 16] [Hematology Reports 2010; 2:e2]
this  is  called  primary  hemostasis.  Secondary
hemostasis occurs simultaneously.62 Proteins
in the blood plasma, called coagulation factors
or clotting factors, respond in a complex cas-
cade to form fibrin strands, which strengthen
the platelet plug (Figure 8). 
Vascular pathology
The vascular system is a complex network of
vessels  connecting  the  heart  with  diverse
organs  and  tissues  to  maintain  their  home-
ostasis in response to physiological and patho-
logical changes. The vascular system is locally
specialized  to  accommodate  widely  varying
blood flow and pressure, and the distinct needs
of individual tissues.
RBC  destruction  is  normally  the  result  of
senescence. Each day about 1% of the RBCs
are removed and replaced. RBC aging is char-
acterized by decreased glycolytic enzyme activ-
ity which leads to decreased energy production
and  subsequent  loss  of  deformability  and
membrane  integrity.  Ninety  percent  of  aged
RBC destruction is extravascular and occurs
mainly in the phagocytic cells of the spleen,
with a small amount occurring in the liver and
bone marrow. Extravascular hemolysis occurs
in three situations: the red cells appear dam-
aged, the red cells are less deformable, and the
red cells are the targets of an immune reac-
tion.  Examples  of  extravascular  hemolysis
include: i) sickle cell disease; during a crisis,
hypoxia results in gelling of the Hb S, the red
cells become less deformable, and phagocyto-
sis  within  mononuclear  cells  in  the  spleen
results  in  extravascular  hemolysis,  and  ii)
hereditary  spherocytosis;  the  abnormal
cytoskeleton reduces the deformability of the
red cells. The clinical features of extravascular
hemolysis  include:  jaundice,  anemia  and  no
hemoglobinuria.  The  serum  haptoglobin  is
reduced because small amounts of free hemo-
globin do enter the blood. Haptoglobin is an
alpha-2-globulin. The function of haptoglobin
is to bind free hemoglobin in the blood, with a
capacity of up to 1.4 grams per liter. The hapto-
globin-hemoglobin complexes are removed by
the reticuloendothelial system, resulting in a
reduction in the concentration of haptoglobin.
It is only when the binding capacity is rapidly
exceeded - in acute hemolysis - that hemoglo-
bin appears in urine. Haptoglobin is an acute
phase protein, rising in concentration during
acute inflammation (Figure 9). 
About 5-10% of RBC destruction is intravas-
cular, occurring in the lumen of the blood ves-
sels. Intravascular hemolysis is less common,
requiring mechanical (prosthetic heart valves
and the microangiopathic hemolysis associat-
ed  with  disseminated  intravascular  coagula-
tion and other processes) or immune (anti-
body-mediated, e.g. transfusion reaction and
complement-mediated, e.g. paroxysmal noctur-
nal hemoglobinuria) disruption of the red cells
within the vascular system. 
Heart valve replacements may be xenografts
such  as  pig  valves,  cadaveric  homografts  or
artificial valves. Bioprostheses are less durable
than artificial valves but the patient does not
need  permanent  anticoagulation.  Pig  valves
are,  therefore,  used  in  the  elderly  and  in
women who want to bear children. Two com-
mon artificial valves are the tilting disc and the
ball-and-cage valve. Each of these valves car-
ries the risk of infective endocarditis, leakage
and  thromboembolism.  Patients  with  these
valves  require  antibiotic  prophylaxis  when
undergoing  any  invasive  procedures.
Replacement  valves  cause  more  trauma  to
platelets and red cells compared to the human
valves they replace. This may be sufficient to
cause  thrombocytopenia  and/or  a  hemolytic
anemia. 
Microangiopathic  hemolytic  anemia  is  an
intravascular hemolysis caused by mechanical
obstruction or narrowing of the microvascula-
ture. Typically, the blood film shows fragment-
ed red blood cells. 
Transfusion of blood and blood products may
be indicated in a variety of situations such as
acute blood loss, correction of anemia, prophy-
lactically before surgery or transfusion of the
newborn. The specific situation will dictate the
most  appropriate  blood  product.  Ideally,  the
patient's blood group and rhesus status should
be known, and blood should be cross-matched
with the proposed donor blood. Otherwise, uni-
versal donor blood (group O negative) is used. 
Paroxysmal nocturnal hemoglobinuria is an
acquired  clonal,  benign,  hematopoietic  stem
cell disorder which results in the formation of
defective red cells, white cells and platelets. It
is  characterized  by  intravascular  hemolysis
and frequent venous thrombosis or bleeding. It
is caused by a mutation in an X-linked gene
involved in the formation of membrane phos-
phatidyl inositol anchors. The membranes of
these cells are deficient in those proteins nor-
mally  anchored  to  the  cell  through  a  phos-
phatidyl  inositol  linkage,  including  comple-
ment deactivating factors. PNH is a very rare
disorder and should be suspected in confusing
cases of hemolytic anemia. There is a median
survival of ten years (Figure 10). 
The vascular pathology of SCD is influenced
by many factors, including adhesiveness of red
and  white  blood  cells  to  endothelium,
increased  coagulation,  and  homeostatic  per-
turbation. The vascular endothelium is central
to  disease  pathogenesis  because  it  displays
adhesion molecules for blood cells, balances
procoagulant and anticoagulant properties of
the vessel wall, and regulates vascular home-
ostasis  by  synthesizing  vasoconstricting  and
vasodilating  substances.  The  occurrence  of
intermittent vascular occlusion in SCD leads to
reperfusion injury associated with granulocyte
accumulation  and  enhanced  production  of
reactive oxygen species. The participation of
nitric oxide (NO) in oxidative reactions caus-
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Figure 9. Extravascular destruction of RBCs.73 Legend: Extravascular hemolysis occurs
when damaged or abnormal RBCs are cleared from the circulation by cells of the spleen,
liver, and bone marrow similar to the process by which senescent RBCs are removed. The
spleen usually contributes to hemolysis by destroying mildly abnormal RBCs or cells coat-
ed with warm antibodies. An enlarged spleen may sequester even normal RBCs. Severely
abnormal RBCs or RBCs coated with cold antibodies or complement (C3) are destroyed
within the circulation and in the liver, which (because of its large blood flow) can remove
damaged cells efficiently.[Hematology Reports 2010; 2:e2]
es a reduction in NO bioavailability and con-
tributes  to  vascular  dysfunction  in  SCD.
Therapeutic strategies designed to counteract
endothelial,  inflammatory,  and  oxidative
abnormalities  may  reduce  the  frequency  of
hospitalization and blood transfusion, the inci-
dence  of  pain,  and  the  occurrence  of  acute
chest syndrome and pulmonary hypertension
in patients with SCD.
Clinical pathology 
Clinical pathology of SCD includes: 1) pain-
less  crises  or  chronic  hemolytic  anemia,
chronic  intravascular  hemolytic  anemia  and
acute episodes of severe anemia, transient red
cell  aplasia  (parvovirus  B19),  acute  splenic
sequestration, acute hemolysis (“hyperhemol-
ysis”); 2) painful crises or vasoocclusion: i)
microvascular occlusion, clinically silent, and
ii)  macrovascular  occlusion,  acute  ischemic/
infarctive damage, pain episodes, stroke, pri-
apism, acute chest syndrome, renal papillary
necrosis and splenic infarction (there are sev-
eral  inter-related  factors  that  impact  on
vasoocclusion in SCD, including RBC density,
RBC rigidity, membrane anomalies, blood vis-
cosity  and  endothelial  cell  adhesion.  These
aspects of vasoocclusion are discussed under
the pathophysiology of SCD); and iii) chronic
organ damage: splenic dysfunction, high risk
of bacterial infection and progressive dysfunc-
tion  of  lungs  (oxyhemoglobin  desaturation,
pulmonary hypertension, kidneys) proteinuria,
renal failure, gallbladder-gallstones, eyes-pro-
liferative  retinopathy,  joints-osteonecrosis,
arthritis, heart-CHF.
Painless crises 
Painless  SCD  crises  or  hemolytic  anemia
may be related to repeat cycles of sickling and
unsickling,  which  interact  to  produce  irre-
versible red cell membrane changes, red cell
dehydration, and erythrocyte destruction. The
painless  SCD  crises  are  hyperhemolysis,
intravascular hemolysis, sequestration, aplas-
tic, megaloblastic (folate deficiency), papillary
necrosis (kidneys) and others. 
Hyperhemolysis: hemolysis is the premature
destruction of RBCs due to intrinsic inherited
defects  in  the  RBCs  or  because  of  acquired
intravascular  abnormalities.  Hyperhemolysis
is a rare life threatening complication of red
cells occurring in multiple transfusions seen
in 4% of pediatric and 1% of adult patients with
thalassemia,  myelofibrosis,  and  anemia  of
chronic  sickle  cell  disease.64 Two  forms  of
hyperhemolysis  are  acute  or  intravascular
hemolysis  (which  usually  presents  within
seven days of a transfusion) and delayed or
extravascular hemolysis. Intravascular hemol-
ysis and chronic anemia is an acute accelerat-
ed  drop  in  hemoglobin  level.  Patients  have
symptoms of fever, hemolysis and hemoglobin-
uria. However, serological findings are usually
negative (direct antiglobulin test/DAT and red
cell alloantibodies), and anemia is compound-
ed by reticulocytopenia, not due to parvovirus
B19  or  red  cell  aplasia.  The  red  blood  cells
break down at a faster rate. This is particular-
ly common in patients with co-existent G6PD
deficiency. While patients with an Hb level of
6-7 g/dL who are able to participate in daily
routine activities in a normal fashion are not
uncommon,  their  tolerance  for  exercise  and
exertion tends to be very limited. In extravas-
cular  hemolysis,  RBCs  are  phagocytized  by
macrophages in the spleen and liver. Causes
include RBC membrane abnormalities such as
bound immunoglobulin, or physical abnormal-
ities  restricting  RBC  deformability  that  pre-
vent  egress  from  the  spleen.  Extravascular
hemolysis is characterized by spherocytes.
Hyperhemolysis is dangerous because both
transfused and autologous red blood cells are
destroyed.  Hemoglobin  counts  after  transfu-
sion are, therefore, lower than before transfu-
sion, and further red cell transfusion exacer-
bates ongoing hemolysis.39,58,64,65
Aplastic crises: these are acute worsenings
of  the  patient's  baseline  anemia,  producing
pallor, tachycardia, and fatigue. This crisis is
triggered  by  parvovirus  B19  (B19V),  which
directly  affects  erythropoiesis  (production  of
red blood cells) in bone marrow, resulting in
cessation of erythropoiesis. Parvovirus infec-
tion nearly completely prevents red blood cell
production for 2-3 days. Coupled with greatly
shortened RBC lifespan, usually 10-20 days, a
very rapid drop in Hb occurs. In normal individ-
uals,  this  is  of  little  consequence,  but  the
shortened red cell life of SCD patients results
in  an  abrupt,  life-threatening  situation.  The
condition  is  self-limited,  with  bone  marrow
recovery  occurring  in  7-10  days,  followed  by
brisk  reticulocytosis.  Most  patients  can  be
managed supportively; some need blood trans-
fusion. 
Megaloblastic changes: anemia may be com-
plicated with megaloblastic changes secondary
to  folate  deficiency.  These  result  from
increased red blood cell turnover and folate uti-
lization. Periodic bouts of hyperhemolysis may
occur. Management is supportive, sometimes
with blood transfusions
Jaundice: jaundice or yellowing of the skin,
eyes, and mouth is a common sign and symp-
tom of SCD. Sickle cells do not live as long as
normal red blood cells and, therefore, they are
dying  more  rapidly  than  the  liver  can  filter
them  out.  The  breakdown  of  red  blood  cells
produces  a  substance  called  bilirubin.
Bilirubin  is  responsible  for  yellowing  of  the
skin and eyes (jaundice) in people with sickle
cell anemia. 
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Figure 10. Intravascular destruction of RBCs.74 Intravascular hemolysis usually occurs
when the cell membrane has been severely damaged by any of a number of different mech-
anisms, including autoimmune phenomena, direct trauma (e.g., march hemoglobinuria),
shear stress (e.g., defective mechanical heart valves), and toxins (e.g., clostridial toxins,
venomous snake bite). It results in hemoglobinemia when the amount of Hb released into
plasma exceeds the Hb-binding capacity of the plasma-binding protein haptoglobin, a
globulin normally present in concentrations of about 1.0 g/L in plasma. With hemoglo-
binemia, unbound Hb dimers are filtered into the urine and reabsorbed by renal tubular
cells; hemoglobinuria results when reabsorptive capacity is exceeded. Iron is embedded in
hemosiderin within the tubular cells; some of the iron is assimilated for reutilization and
some reaches the urine when the tubular cells slough.[page 18] [Hematology Reports 2010; 2:e2]
Painful crises 
Vasoocclusive  phenomena  and  hemolysis:
occlusion of the microvasculature by sickled
erythrocytes  is  the  most  common  clinical
painful  crisis  and  hallmark  of  SCD  during
adult life.66 This process leads both to typically
self-limited  episodes  of  pain  as  well  as  a
panoply  of  end-organ  damage,  including
acquired  functional  asplenia,  sickle  cell
nephropathy,  hepatic  sequestration,  acute
chest syndrome, priapism, pulmonary emboli,
osteonecrosis, and ultimately damages every
organ system including the retinae, liver, and
kidneys. The crisis is precipitated by factors
such as infection (25% of incidences); human
parvovirus  B19  (common  viral  cause);  cold
weather due to reflex vasospasm, and dehydra-
tion in warm weather. Its symptoms, which are
recurrent painful crises and sudden onset of
pain  in  a  variety  of  organs  including  the
extremities, long bones, abdomen, chest, back
and joints, occur in children under 18 years. It
can lead to fever, malaise, leukocytosis, hypox-
ia,  ischemia,  ultimately  tissue  damage,  life-
long  disabilities  and/or  early  death.  Miller,
Sleeper, Pegelow, et al. are of the opinion that
painful vaso-occlusive complication of SCD is
more likely to have adverse outcomes in later
childhood,  including  death,  stroke,  frequent
pain,  and  recurrent  acute  chest  syndrome
(ACS).67
The clinical manifestations of vasoocclusion
result from a dynamic combination of abnor-
malities in hemoglobin structure and function,
red blood cell membrane integrity, erythrocyte
density, endothelial activation, microvascular
tone, inflammatory mediators, and coagulation
factors. Tissue injury is usually produced by
ischemia and infarction. The organs at great-
est risk are those with venous sinuses where
blood flow is slow and oxygen tension and pH
are low (e.g. spleen and bone marrow) or those
with a limited terminal arterial blood supply
(e.g. eye, head of the femur and humerus). No
tissue  or  organ  is  spared  from  this  injury.
Symptoms of the hypoxic injury may be either
acute  (e.g.  painful  events,  acute  chest  syn-
drome)  or  insidious  in  onset  (e.g.  aseptic
necrosis of the hips, sickle cell retinopathy).
The effects of acute and chronic tissue injury
may ultimately result in failure of organs like
the kidney, particularly as the patient ages.
The  frequency,  severity,  and  duration  of
these crises vary considerably. It may last sev-
eral hours to several days and terminate as
abruptly as it began. Severe painful crises are
treated with hydration and analgesics (PCA),
as well as intravenous opioid administration at
regular intervals until the crisis has settled.
Diphenhydramine is sometimes effective for
the  itching  associated  with  the  opioid  use.
Incentive spirometry, a technique to encour-
age deep breathing to minimize the develop-
ment of atelectasis, is recommended. NSAIDs
(such as diclofenac or naproxen) may be used
in the management of milder crises.
Central nervous system: another painful cri-
sis is the central nervous system (CNS) com-
plication. Complications involving the central
nervous system are among the most devastat-
ing manifestations of SCD. The most common-
ly reported neurological complications for SCD
are overt stroke and increased blood flow to the
brain.46 A high frequency of silent infarction,
leukoencephalopathy, and cerebral atrophy, is
revealed by screening neuroimaging studies in
asymptomatic SCD patients. The high preva-
lence of these findings in the youngest SCD
patients underscores the fact that CNS injury
begins early in life. Ischemic stroke is the most
common brain injury and accounts for about
12% of deaths in children with SCD (mean age
eight years).38 The most common intracranial
vessels affected are the distal internal carotid,
proximal middle cerebral, and anterior cere-
bral arteries. Vasculopathy of these large ves-
sels  is  most  often  associated  with  cortical
infarction. 
Other  manifestations  of  cerebral  insult,
such as neurocognitive delay and behavior dif-
ficulties, are also frequently reported in this
patient  population.  The  use  of  transcranial
Doppler ultrasonography screening allows the
identification of patients at high risk for clini-
cal  stroke  as  well  as  stroke  prevention  by
chronic transfusion.38
Acute chest syndrome: this is a spectrum of
pulmonary pathology, characterized by a new
pulmonary infiltrate on chest X-ray, often asso-
ciated with an increased oxygen requirement,
respirophasic  pain,  fever,  tachypnea,  cough,
wheezing, and dyspnea. It is an acute multi-
factorial process and life-threatening compli-
cation of sickle cell anemia. Common causes
include lung infection (Chlamydia pneumoni-
ae, Mycoplasma pneumoniae, and respiratory
syncytial virus), pulmonary infarction, sickle
cells blocking blood vessels, bone marrow or fat
embolism, and surgical procedures. At the level
of  the  pulmonary  endothelial  cell,  an  imbal-
ance between adhesive forces and nitric oxide
is created, favoring intrapulmonary sickle cell
adhesion.  In  SCDs,  the  incidence  of  ACS  is
33%  in  patients  with  Hgb  S-ʲ0 thalassemia,
50% in patients with Hgb SC, and 25% or less
in patients with Hgb S-ʲ+ thalassemia.68 Up to
20% of children in the peri-operative period
will have an episode of ACS, with the highest
risk being the age group between two and four
years.69 ACS usually develops 48 to 72 hours
after the surgical procedure and may not be
immediately obvious. ACS is the second most
common complication of SCD, with a rate of
12.8 cases per 100 patient years, and is the
leading cause of death, being responsible for
up to 25% of sickle cell deaths.70 The mortality
rate in children is 1.1% and 3% overall.71
Abdominal  complications  in  SCD  include
hepato-biliary complications, high incidence of
gallstones caused by the continual high levels
of bilirubin excretion consequent to chronic
hemolysis,  acute  and  chronic  cholelithiasis,
acute  splenic  sequestration,  duodenal  ulcer,
and renal failure.
Hepato-biliary complications occur predomi-
nantly in patients with homozygous sickle cell
anemia, and to a lesser extent in patients with
sickle cell trait, Hb SC disease and Hb S b tha-
lassemia. The hepatic disorder may primarily
be caused by the sickling process, but more
commonly arises as a consequence of the mul-
tiple  transfusions  that  these  individuals
require in their lifetime, of the superimposi-
tion of hepatitis by hepatotropic or non-hepa-
totropic viruses, by other infections, cholelithi-
asis or as a result of vascular phenomena relat-
ed  to  the  primary  disease  itself.  The  term
multi-transfusion hepatopathy may, therefore,
be more appropriate for these individuals. 
Sickle  cell  hepatopathy  encompasses  a
range  of  abnormalities  arising  from  a  wide
variety of insults to the liver and biliary tracts
in patients with SCD. These include hepato-
megaly,  increases  in  serum  bilirubin  and
transaminase levels, and occasionally increas-
es in the levels of other markers indicative of
disorders of the liver and bile canaliculus.
Hepatomegaly  was  detected  at  physical
examination  in  48.9%  of  the  patients,  com-
pared to an incidence of 30.4% of this finding
at ultrasonography.58,64,72-74
The direct manifestations of sickle cell dis-
order in the liver relate predominantly to vas-
cular occlusion with acute ischemia, seques-
tration,  and  cholestasis.  The  main  hepatic
complications of multiple transfusions include
acute and chronic infection with hepatitis B
and C and iron overload. Liver dysfunction may
vary from a self-limiting cholestasis to cases of
cirrhosis  and  liver  failure;  however,  severe
liver  disease  rarely  occurs  in  these  patients
unless other concomitant pathologies, such as
infection  with  hepatitis  C  virus  (HCV)  or
human  immunodeficiency  virus  (HIV)  are
present.58,64,73 Other  clinical  characteristics
suggestive of liver failure are flapping tremor
and  spider  nevi.  Liver  involvement  is  not
extremely severe. 
A  further  potential  consequence  of  the
chronic hemolysis is the development of pig-
ment  stones,  with  consequent  cholecystitis
and acute and chronic biliary obstruction from
choledocholithiasis. Cholelithiasis is more fre-
quent in patients with Hb SS and S/Sʲ0 tha-
lassemia  electrophoretic  patterns,  who  have
higher  indirect  bilirubin  levels,  and  is  less
common in Hb SC patients, in whom hemoly-
sis and consequently indirect hyperbilirubine-
mia are less severe.75
Extremities: other painful crises are those
involving  the  extremities  – ulcers,  aseptic
necrosis,  and  priapism  among  others.  Skin
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ulcers are chronic painful open sores on the
legs. They result from minor injury to the area
around the malleoli. Because of relatively poor
circulation,  compounded  by  sickling  and
microinfarcts, healing is delayed and infection
is established. 
Infarction of the penis is a condition called
priapism. Priapism is a sustained, painful, and
unwanted  erection  of  the  penis  that  patho-
physiologically is the result of either increased
arterial inflow (i.e., high flow) or, more com-
monly, the failure of venous outflow (i.e., low
flow), resulting in blood trapping within the
erectile bodies.18 It tends to occur repeatedly.
Priapism can be classified as prolonged if it
lasts for more than three hours or as stuttering
if it lasts for more than a few minutes but less
than three hours and resolves spontaneously.
Stuttering episodes may recur or develop into
more prolonged events. Prolonged priapism is
an emergency that requires urological consul-
tation.  Recurrent  episodes  of  priapism  can
result in fibrosis and impotence, even when
adequate treatment is attempted.
During  pregnancy,  intrauterine  growth
retardation,  spontaneous  abortion,  and  pre-
eclampsia may occur. Pregnancy represents a
special area of concern. The high rate of fetal
loss is due to spontaneous abortion. Placenta
previa  and  abruption  are  common  due  to
hypoxia and placental infarction. At birth, the
infant  is  often  premature  or  has  low  birth
weight.
Chronic organ damage
Chronic  organ  damage:  these  are  splenic
sequestration crises, acute papillary necrosis
in the kidneys, opthalmological complications,
avascular necrosis (aseptic bone necrosis) and
pulmonary complications
Splenic  sequestrations  are  acute,  painful
enlargements of the spleen in the latter part of
the first year of life due to pooling of large
numbers  of  sickled  cells.  The  abdomen
becomes bloated and very hard. Severe acute
splenic  sequestration  produces  hypovolemia
and  cardiovascular  decompensation.  The
spleen  undergoes  repeated  infarction.  After
repeated episodes of splenic sequestration, the
spleen becomes scarred, fibrotic, shrinks and
is permanently damaged. Most children, by the
age of eight years old, do not have a function-
ing  spleen  either  from  surgical  removal,  or
from repeated episodes of splenic sequestra-
tion. Spleen is non-functional. Management is
supportive, sometimes with blood transfusion.
Overwhelming  post-(auto)splenectomy  infec-
tion (OPSI), which is due to functional asple-
nia, is caused by encapsulated organisms such
as  Streptococcus  pneumoniae and  Haemo-
philus influenzae. Daily penicillin prophylaxis
is the most commonly-used treatment during
childhood, with some hematologists continu-
ing  treatment  indefinitely.  Patients  benefit
today from routine vaccination for H. influen-
zae,  S.  pneumoniae,  and  Neisseria  meningi-
tidis. 
Acute papillary necrosis in the kidneys: the
internal environment of the kidney is particu-
larly prone to damage from sickle cells. Signs
of  kidney  damage  can  include  blood  in  the
urine,  incontinence,  and  enlarged  kidneys.
Adults with SCD often experience insufficient
functioning of the kidneys, which can progress
to kidney failure in a small percentage of adult
patients.  Nephrotic  syndrome  is  uncommon
but may occur.76
Opthalmological  complications:  paraorbital
facial infarction may result in ptosis, when the
tiny blood vessels that supply oxygen to the
retina, the tissue at the back of the eye, may be
blocked by sickle cells, leading to conditions
called  retinopathy,  proliferative  retinopathy,
vitreous  hemorrhages  and  retinal  detach-
ments, resulting in blindness. Regular annual
ophthalmology examination is recommended. 
Avascular necrosis (aseptic bone necrosis)
especially in weight bearing areas such as the
femur of the hip and other major joints occur
as  a  result  of  ischemia,  which  is  repeated
infarction of joints, bones, and growth plates.
This complication is associated with chronic
pain and disability, and may require changes
in employment and lifestyle (Figure 11).
Pulmonary complications of sickle cell ane-
mia  include  reactive  airway  disease  (pul-
monary  hypertension),  pulmonary  throm-
boembolism,  and  acute  chest  syndrome.
Pulmonary hypertension (increased pressure
on the pulmonary artery), leading to strain on
the right ventricle and a risk of heart failure;
typical  symptoms  are  shortness  of  breath,
decreased exercise tolerance and episodes of
syncope.77This may be due in part to the deple-
tion of nitric oxide. Various studies have found
that more than 40% of adults with SCD have
pulmonary  hypertension  that  worsens  with
age.  Intravascular  hemolysis,  by  scavenging
nitric oxide and causing endothelial cell dys-
function, may play a role in the development of
pulmonary  hypertension.  Echocardiographic
studies have reported that approximately 30%
of screened adult patients with sickle cell ane-
mia  have  pulmonary  hypertension  (systolic
pulmonary  artery  pressures  (PAP)≥30  mm
Hg).77 Recent autopsy studies suggest that up
to 75% of sickle cell patients have histological
evidence of pulmonary arterial hypertension at
the  time  of  death.78 Similarly,  retrospective
studies  have  demonstrated  that  40-50%  of
patients  with  thalassemia  intermedia,79 and
10-75%  of  patients  with  thalassemia  major,
have echocardiographic evidence of pulmonary
hypertension.80
Clinical severity of sickle cell disor-
der symptoms 
The  clinical  course  of  sickle  cell  anemia
does not follow a single pattern; some patients
have mild symptoms, while others have very
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Figure 11. Avascular necrosis (osteonecrosis) of bone. Avascular necrosis of the hip occurs
when blood flow to the top portion of the thighbone (femur) is interrupted. The affected
portion of the bone consists of the head (the ball-shaped piece of bone that fits into the
socket of the hip) and neck (the portion of the thighbone just below the head). When it’s
deprived of blood, this part of the bone begins to “die,” breaking down and causing the
cartilage on top of it to collapse.[page 20] [Hematology Reports 2010; 2:e2]
severe  symptoms.  Symptoms  may  be  less
severe or different in children who have inher-
ited a sickle cell gene from one parent and a
different abnormal hemoglobin gene from the
other. The clinical symptoms can be precipitat-
ed by fever, infection, excessive exercise, tem-
perature  changes,  hypoxia,  and  hypertonic
solutions.  The  clinical  severity  of  the  symp-
toms experienced is related to the concentra-
tion of Hb S in the red blood cell and expres-
sion of other hemoglobins, endothelial factors,
nitric oxide and other factors.
Etiology of different types of anemia 
Many factors contribute to the occurrence of
painless and painful crisis in sickle cell disor-
ders. For instance, anemia which is inadequate
production  of  hemoglobin  exists  in  various
forms (nutritional anemia, aplastic or hypoplas-
tic anemia, hemolytic anemia; acute anemia;
and  chronic  iron  deficiency  anemia)  and  as
such  is  usually  triggered  by  diverse  factors.
Nutritional  anemia  is  usually  precipitated  by
deficiency of blood making ingredients such as
iron, folate or vitamin B12. Aplastic or hypoplas-
tic  anemia  is  usually  triggered  by  depressed
bone marrow activity for red blood cells, white
cells and platelets or any combination of them.
Acute anemia is usually triggered by rapid blood
loss. Chronic iron deficiency anemia is usually
precipitated by slow blood loss.
Infections in SCD such as malaria, pneumo-
nia, septicemia, meningitis, osteomyelitis, and
aplastic crisis are caused by organisms like plas-
modium  falciparum,  S.pneumoniae (pneumo-
cocci), salmonella species, and parvovirus 19.
Other factors which may trigger sickle cell
crises  include  sudden  exposure  to  colder  or
hotter environment or rainfall, undue physical
exertion e.g. sports, low pH or acidity, some
reaction to food/others, hypoxia, dehydration
e.g.  after  alcoholic  binge,  water  deprivation,
fever, and emotional or mental stress.
Treatment for sickle cell disorders
The management of SCD continues to be
supportive and includes hydration, pain relief,
blood  transfusion  and  production  of  fetal
hemoglobin (HbF).
Hydration
Drinking plenty of water daily (8 to 10 glass-
es) or receiving fluid intravenously (to prevent
and treat pain crises).
Blood transfusions
Blood transfusions may be used for anemia
and to prevent stroke. They may also be used to
dilute the HbS with normal hemoglobin to treat
chronic  pain,  acute  chest  syndrome,  splenic
sequestration,  and  other  emergencies.  Used
correctly,  transfusion  can  be  life-saving  and
prevent  progressive  organ  damage.  Blood
transfusion not only increases the oxygen-car-
rying capacity of blood but also decreases the
percentage of cells capable of sickling. It is rec-
ommended that transfusion should be carried
out  with  phenotypically  matched,  leuko-
reduced, sickle cell negative blood in order to
attain a post-transfusion hematocrit of about
36%.81 The  complications  of  transfusion  are
well known and include allo- and autoimmu-
nization, iron overload, and the transmission
of infectious diseases such as hepatitis and
HIV. Physicians caring for sickle cell patients
must understand specific indications, types of
red cell preparations, complications of transfu-
sion  therapy,  and  methods  to  minimize
adverse events. 
Bone marrow transplantation
Bone marrow transplant has been effective
in curing some patients with sickle cell dis-
ease. The decision to undergo this procedure
is based on the severity of the disease and abil-
ity to find a suitable bone marrow donor. A con-
siderable number of patients with sickle cell
anemia worldwide have undergone successful
bone marrow transplantation.82 Only selected
patients are eligible for the procedure. Even
then, bone marrow transplantation was associ-
ated with a 5-10% mortality, mostly from graft-
versus-host disease.
Production of fetal hemoglobin
Another approach to reducing the effect of
HbS polymer formation has been to augment
the  production  of  fetal  hemoglobin  (HbF).
Through population and clinical observation, it
has  long  been  recognized  that  higher  blood
HbF levels correlate with fewer clinical mani-
festations of SCD. Pharmacological manipula-
tion of HbF in the therapy of sickling disorders
has  been  proposed  since  the  mid-1950s.  To
date, several agents have been tried, but the
safest  and  most  effective  has  proven  to  be
hydroxyurea.83 The  mechanism  of  increased
HbF  production  by  hydroxyurea  is  not  fully
understood.  Also,  recent  studies  have  found
that hydroxyurea contributes to the production
of nitric acid, a potent endothelial relaxing fac-
tor.84
Hydroxyurea  is  a  medication  that  has
recently been developed that may help reduce
the frequency of pain crises and acute chest
syndrome. It is a cytotoxic and cytoreductive
antimetabolite that acts via inhibition of DNA
synthesis by inhibiting ribonucleotide reduc-
tase.  Known  pharmacological  effects  of
hydroxyurea that may contribute to this drug’s
efficacy in SCD include increased red cell con-
tent of hemoglobin F levels (which reduces the
formation  of  hemoglobin  S  polymers),  dose-
related  cytoreductive  effects  on  neutrophils,
increased water content of red cells, increased
deformability  and  successful  microvascular
navigation of sickled cells, and altered adhe-
sion  of  red  blood  cells  to  endothelium  by
decreasing the expression of endothelial adhe-
sion molecules. It is associated with signifi-
cant  decreases  in  the  yearly  rate  of  painful
crises, hospital admissions, incidence of chest
syndrome,  priapism,  hepatic  sequestration,
and  blood  transfusion  requirements  by  as
much  as  50%.  Hydroxyurea  treatment  also
reduces  mortality  by  40%.85 Hydroxyurea  is
indicated  for  adults  with  SCD  who  require
three or more hospital admissions for vasooc-
clusive crises per year, and should also be con-
sidered  for  symptomatic  children  and  for
patients  with  organ  dysfunction.  The  long-
term effects of the medication, however, are
unknown.
Prophylactic therapy
Three prophylactic measures have become
widely accepted in the management of SCD:
penicillin prophylaxis (to prevent infections),
immunization  against  pneumococcal  infec-
tion, and folate administration (to help prevent
severe  anemia).  The  mortality  rate  due  to
Streptococcus pneumoniae, sepsis, and menin-
gitis was historically very high in children with
SCD under the age of six. This rate has been
lowered  tremendously  by  three  maneuvers.
The first is diagnostic screening for SCD in
neonates,  with  immediate  initiation  of  pen-
cillin VK 125 mg twice daily, increased at the
age of three years to 250 mg twice daily and
continued until the age of five. The second is
immunization  with  heptavalent  pneumococ-
cal-conjugated vaccine at two, four, six, and 12
months of age. The third is immunization with
23-valent  pneumococcal  polysaccharide  vac-
cine at two and five years of age.86 Due to the
increased  metabolic  requirement  for  folate,
this is frequently provided as a supplement at
a dose of 1 mg daily, although the adequate
dietary intake in the United States appears not
to endorse such supplementation.
Implications for counseling and
psychotherapy 
The implications of the pathological basis of
SCD for counseling and psychotherapy can be
viewed on two planes. 
Implications for professionals
The pathological basis of SCD has profound
implications  for  psychotherapists,  genetic
counselors, psychologists (particularly clinical
psychologists) and informal help-givers includ-
ing the spiritual help-givers. The pathological
basis of SCD has generated some questions.
Are the psychotherapists and counselors suffi-
ciently equipped to adequately meet the psy-
chological needs of the individuals living with
SCD? Are the professionals (such as psycholo-
gists  and  counselors)  seeing  the  need  to
explore  the  possibility  of  blending  pharma-
cotherapy with culturally accepted psychother-
apeutic interventions for dealing with pain and
promoting  a  steady  state  among  individuals
living  with  SCD?  This  article  thus  becomes
useful information in the hands of clinical psy-
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chologists  and  genetic  counselors  to  assist
them in better helping individuals living with
SCD from a psychotherapeutic perspective. As
a  result,  professionals  should  focus  on  the
development of cross-cultural psychotherapeu-
tic measures that will address specific needs of
individuals living with SCD.
In addition, the study has also shown the
need for a counseling and psychotherapeutic
package.  Since  it  has  been  established  that
there are certain psychological variables that
affect individuals living with SCD, and all of
the significant persons around them may not
be trained psychologists, it therefore implies
that there is the urgent need to train enough
psychotherapists with a special focus on SCD.
These trained professionals would be able to
provide a holistic solution to those who come
to them for help. 
It is also necessary to develop cross-cultural-
ly relevant therapeutic packages that will take
into consideration the psychological, cultural
and spiritual aspects of individuals living with
SCD  in  order  to  provide  them  with  holistic
care. In other words, an eclectic but harmo-
nious  combination  of  behavioral  techniques
(therapeutic interventions) and cross-cultural
therapeutic techniques could be more potent
in achieving desirable therapy outcomes. Even
though  many  organizations  are  providing
counseling and psychotherapy, how many are
focused on the psychological aspects of sickle
cell disorders? There is also the urgent need
for  research  that  would  assess  the  level  of
counseling and therapy being offered to indi-
viduals  living  with  SCD  during  their  crisis
state and steady state, whether they are appro-
priate, and whether they are being implement-
ed  properly.  Appropriate  psychological  inter-
ventions can profoundly alter sets of beliefs,
ways of thinking, affective states and behavior
patterns of individuals living with SCD.
Socio-economic implications
The  psychological  challenges  of  SCD  also
have economic implications among individuals
living with the disease and their families. A
thorough understanding of these issues is cru-
cial in coming up with appropriate interven-
tion strategies. Understanding the ‘enemy’ is a
critical tool in overpowering him/her.
Recommendation
The magnitude of SCD in Nigeria and Africa
on the whole is alarming. Numerous families
have lost loved ones to this red blood cell disor-
der. Health care providers and policy makers
must not be indifferent to it, but rather sensi-
tize the Government to provide  equitable and
effective treatment facilities for affected per-
sons, encourage early presentation by creating
awareness, promote further training of genet-
ic  counselors,  provide  adequate  and  reliable
laboratory  diagnostic  facilities,  and  support
molecular, clinical and operational research.
Conclusions
Awareness of SCD is paradoxically low in
sub-Saharan Africa as increasing survival and
prevalence are a largely recent phenomenon.
Greater familiarity with SCD due to increasing
survival and prevalence creates a widespread
desire to do something about SCD. 
Problems in affected families include igno-
rance, lack of access to good services, frequent
child illness and death, increased anxiety, and
superstition and stigmatization. African gov-
ernments should provide equitable and effec-
tive treatment facilities for affected persons.
There is also the need to train more clinical
psychologists  and  genetic  counselors  in  the
psychological aspects of SCD. Trained profes-
sionals would be able to craft holistic care for
the treatment and management of SCD crisis
among individuals living with this disease.
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